Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04

Cancer
Mark G CarmichaelGeorge E Peoples

Abstract

HER-2/neu, overexpressed in breast cancer, is a source of immunogenic peptides that include GP2 and E75. Phase 2 testing of E75 as an adjuvant vaccine has suggested a clinical benefit. GP2, derived from the transmembrane portion of HER-2/neu, has differing binding characteristics and may be more immunogenic than E75. Results of the first phase 1 trial of GP2 peptide vaccine are presented. Disease-free, lymph node-negative, human leukocyte antigen (HLA)-A2(+) breast cancer patients were enrolled. This dose escalation trial included 4 groups to determine safety and optimal GP2 peptide/granulocyte-macrophage colony-stimulating factor (GM-CSF) dose. Toxicities were monitored. Immunologic response was assessed ex vivo via the HLA-A2:immunoglobulin dimer assay to detect GP2-specific CD8(+) T cells (and E75-specific CD8(+) T cells to assess epitope spreading) and in vivo via delayed type hypersensitivity (DTH) reaction (medians/ranges). Eighteen patients were enrolled. All toxicities were grade < or =2. Eight (88.9%) of 9 patients in the first 3 dose groups required GM-CSF dose reductions for local reactions > or =100 mm or grade > or =2 systemic toxicity. GM-CSF dose was reduced to 125 microg for the final dose group. All patients re...Continue Reading

References

Sep 4, 1975·The New England Journal of Medicine·J E Sokal
Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S ToikkanenH Joensuu
Jan 17, 1995·Proceedings of the National Academy of Sciences of the United States of America·G E PeoplesT J Eberlein
Jan 1, 1993·Annual Review of Immunology·H G RammenseeO Rötzschke
Nov 1, 1995·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·B FiskC G Ioannides
Jun 9, 2004·Cancer Immunology, Immunotherapy : CII·E Claire DeesJonathan S Serody
Sep 15, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George E PeoplesSathibalan Ponniah
Oct 26, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew T HuemanGeorge E Peoples
Jul 26, 2006·Annals of Surgical Oncology·Elizabeth A MittendorfGeorge E Peoples
Feb 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·George E PeoplesSathibalan Ponniah
Jul 18, 2008·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·UNKNOWN Alzheimer's Association

❮ Previous
Next ❯

Citations

Sep 13, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Tomer GranotDaniel Meruelo
Nov 30, 2011·Nature Reviews. Clinical Oncology·Carlos L ArteagaLuca Gianni
Apr 16, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A MilaniG Valabrega
Jan 22, 2011·Pathology Research International·Holly Graves, Brian J Czerniecki
Dec 3, 2014·Journal of Inorganic Biochemistry·Shibojyoti LahiriDipak Dasgupta
Nov 3, 2010·Nanomedicine·Jie GaoYajun Guo
Feb 25, 2011·Future Oncology·Yan Liu, Jiayuh Lin
Aug 25, 2012·Future Medicinal Chemistry·Verena M AhrensAnnette G Beck-Sickinger
Feb 5, 2014·Immunotherapy·Soudeh Ghafouri-FardSanaz Tabarestani
Aug 10, 2012·Expert Review of Vaccines·Constantin N BaxevanisSonia A Perez
Dec 21, 2012·Expert Review of Anticancer Therapy·Leisha A Emens
Jun 23, 2011·Expert Review of Vaccines·Elizabeth A MittendorfGeorge E Peoples
Sep 8, 2011·Expert Opinion on Biological Therapy·Alan K SearsGeorge E Peoples
Nov 3, 2015·Biotechnology Advances·Lívia de Paula PeresMarcelo José Barbosa Silva
Oct 26, 2011·Nanomedicine : Nanotechnology, Biology, and Medicine·Seyed Amir JalaliMahmoud Reza Jaafari
Aug 5, 2015·Vaccine·Gregory A CherryholmesMary L Disis
Mar 24, 2012·Journal of Surgical Oncology·Kevin S CliveElizabeth A Mittendorf
Nov 17, 2015·Immunotherapy·Guy T CliftonGeorge E Peoples
Apr 1, 2015·Immunology·Valentina A Zavala, Alexis M Kalergis
Sep 1, 2015·Seminars in Oncology·Joseph ObeidCraig L Slingluff
Jul 10, 2010·Journal of Biomedicine & Biotechnology·Anastas PashovThomas Kieber-Emmons
Aug 21, 2013·Human Vaccines & Immunotherapeutics·Lingxiao ZhaoHua Cong
Dec 20, 2014·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Michiko HaraoLaszlo G Radvanyi
May 3, 2014·Therapeutic Advances in Vaccines·Joseph D Comber, Ramila Philip
Jun 7, 2018·Cancer Biotherapy & Radiopharmaceuticals·Naipeng CuiChuanwei Yang
May 29, 2014·Expert Review of Clinical Immunology·Elham MohitMojgan Allahyari
Jan 10, 2020·Archivum Immunologiae Et Therapiae Experimentalis·Atefeh ArabJavad Behravan
Nov 2, 2017·Oncotarget·Leonardo MirandolaMaurizio Chiriva-Internati
Feb 25, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Maurizio Zanetti
Oct 31, 2019·Journal of Hematology & Oncology·E KrasniqiP Vici
Mar 30, 2010·Expert Opinion on Therapeutic Patents·Luigi Aurisicchio, Gennaro Ciliberto
Apr 26, 2018·International Journal of Cancer. Journal International Du Cancer·Aydah Al-AwadhiNuhad K Ibrahim
Dec 4, 2016·Cancer Metastasis Reviews·Alison Spellman, Shou-Ching Tang
Oct 31, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexis DesrichardTimothy A Chan
Jan 11, 2011·Cancer Research·Véronique CorbièrePierre G Coulie
Jul 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A MilaniG Valabrega
Aug 28, 2021·Journal of Personalized Medicine·Anna BurguinFrancine Durocher
Dec 22, 2021·Expert Review of Vaccines·Maryam Abbaspour, Vajihe Akbari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.